- Home
- » Tags
- » Catumaxomab
Top View
- The Next Generation of Monoclonal Antibody
- Destruction of Tumor Cells Expressing Low to Medium Levels of Tumor Associated Target Antigens by Trifunctional Bispecific Antibodies
- Research and Clinical Landscape of Bispecific Antibodies for The
- Subcutaneous Administratio
- Australian Public Assessment Report for Catumaxomab
- Four-In-One Antibodies Have Superior Cancer Inhibitory Activity Against
- Bispecific Antibodies Targeting Tumor-Associated Antigens And
- Targeted Treatment of Ovarian Cancer - the Multiple - Kinase - Inhibitor Sorafenib As a Potential Option
- International Nonproprietary Names for Pharmaceutical Substances (INN)
- Assessing the Potential Clinical Impact of Reciprocal Drug Approval Legislation on Access to Novel Therapeutics in the USA: a Cohort Study
- For Treatment of Peritoneal Carcinomatosis in Patients with Gastric Cancer
- Book Early and Save up to £540!
- Antibody Therapy of Cancer
- An Anti-Epcam Antibody Epab2-6 for the Treatment of Colon Cancer
- Removab® in Malignant Ascites New
- Monoclonal Antibodies in Gastrointestinal Cancers
- Target Treatment and Symptoms Management
- Monoclonal Antibodies Specific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Over- for Cancer Therapy
- Outpatient Catumaxomab Therapy in Metastatic
- Adverse Events to Monoclonal Antibodies Used for Cancer Therapy Focus on Hypersensitivity Responses
- Bispecific Antibodies and Their Applications Gaowei Fan1,2, Zujian Wang3, Mingju Hao1,2 and Jinming Li1,2*
- 22 November Harlan
- Tumor Immunity Immunotherapy of Cancer
- Removab, INN-Catumaxomab
- Palliative Treatment of Malignant Ascites: Profile of Catumaxomab
- Advances in CD30- and PD-1-Targeted Therapies for Classical Hodgkin Lymphoma Yucai Wang1, Grzegorz S
- Biologic Therapy in Head and Neck Cancer: a Road with Hurdles
- Catumaxomab with Activated T-Cells Efficiently Lyses Chemoresistant
- UC Irvine UC Irvine Previously Published Works
- Working Minutes of the Ephmra Classification Committee
- Targeting Epcam by a Bispecific Trifunctional Antibody Exerts
- Bispecific Antibodies for Cancer Therapy: the Light at the End of the Tunnel?
- Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations a Coulson, a Levy, M Gossell-Williams
- Immunotherapy of Recurrent B-Cell Malignancies After Allo-SCT with Bi20 (FBTA05), a Trifunctional Anti-CD3 Â Anti-CD20 Antibody and Donor Lymphocyte Infusion
- Epcam As a Target in Cancer Therapy
- Effective Relief of Malignant Ascites in Patients
- Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
- Monoclonal Antibodies As Cancer Therapeutics
- Developments in Therapy with Monoclonal Antibodies and Related Proteins
- Antibody Therapies in Cancer
- First Surgical Experience of Intraperitoneal Treatment with the Trifunctional Antibody Catumaxomab (Anti-Epcam × Anti-CD3) for Epithelial Ovarian Cancer
- Epcam Monoclonal Antibodies